Your session is about to expire
← Back to Search
Post-Operative Use of Salt Poor Albumin Solution in Resuscitation of Orthotopic Liver Transplant
N/A
Waitlist Available
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
All Individual Drugs Already Approved
No Placebo-Only Group
Summary
The purpose of the study is to examine if outcome after liver transplantation is improved by using albumin infusion post-transplantation.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Awards & Highlights
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Albumin groupExperimental Treatment1 Intervention
Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
Group II: Control GroupActive Control1 Intervention
Patients in this group will not be allowed albumin or any other colloids fluid for the first 7 days post-operative
Find a Location
Who is running the clinical trial?
McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
471 Previous Clinical Trials
166,857 Total Patients Enrolled